A Study of Lasmiditan on the Heart in Healthy Participants
- Registration Number
- NCT03465436
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The purpose of this study was to determine how two doses of lasmiditan affected the heart in healthy participants. The study also evaluated how much lasmiditan got into the blood stream and how long it took the body to get rid of it. Information about side effects was collected. The study lasted a maximum of 46 days for each participant, not including screening.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 56
-
Body mass index within 18.5 and 29.9 kilograms per meter squared (kg/m²)
-
In good physical and mental health as determined by the following:
- Complete medical history
- Complete physical examination
- Vital signs including blood pressure (supine and standing), heart rate (supine and standing), respiratory rate, and temperature
- Standard 12-lead ECG (triplicate ECG), followed by a 24-hour Holter ECG for arrhythmia monitoring
- Clinical laboratory tests
-
Any of the following cardiac abnormalities on safety screening ECG:
- QTcF interval >430 milliseconds (ms) for males, >450 ms for females
- Unusual T wave morphology or flattened low voltage T waves
- PR interval >240 ms or <110 ms
- Second-degree or third-degree atrioventricular block
- ECG evidence of complete left or right bundle branch block
- Intraventricular conduction delay or QRS duration >110 ms
- Supine resting heart rate <45 beats per minute (bpm) or >90 bpm
- Pathological Q-waves
- Evidence of ventricular pre-excitation
-
Participants with a history of syncope, cardiac arrest, cardiac arrhythmia or torsade de pointes, or structural heart disease
-
Participants with a family history of Long QT syndrome
-
History of allergic hypersensitivity to lasmiditan or any component of the formulations
-
History or current evidence of abuse of any drug substance, licit or illicit, including alcohol; a positive urine screen for drugs of abuse
-
Participants with a history of postural hypotension or fainting
-
Participant is not able to understand and comply with study requirements, instructions and study restrictions
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Placebo Placebo Placebo for lasmiditan and placebo for moxifloxacin administered on Day 1 in one of four treatment periods. Moxifloxacin Moxifloxacin A single, PO dose of moxifloxacin administered on Day 1 in one of four treatment periods. 100 milligrams (mg) Lasmiditan Lasmiditan A single, PO dose of 100 mg lasmiditan administered on Day 1 in one of four treatment periods. 400 mg Lasmiditan Lasmiditan A single, PO dose of 400 mg lasmiditan administered on Day 1 in one of four treatment periods.
- Primary Outcome Measures
Name Time Method Change From Time Matched Baseline in Mean Fridericia-Corrected QT (QTcF) Values of Lasmiditan and Moxifloxacin Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and R-R wave (RR), which is the interval between two R waves. PR is the interval between the P wave and the ventricular depolarization wave (QRS) complex.
- Secondary Outcome Measures
Name Time Method Change From Baseline in Mean Heart Rate (HR) of Lasmiditan and Moxifloxacin Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose Heart rate was determined during ambulatory blood pressure monitoring (ABPM).
Number of Incidents in Electrocardiogram (ECG) Abnormalities in QTcF Interval Greater Than 450 Milliseconds Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose ECGs were assessed for morphology abnormalities or changes in QTcf interval greater than 450 milliseconds by a board-certified cardiologist
Change From Baseline in Mean Cardiac Intervals:QRS of Lasmiditan and Moxifloxacin Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose ECGs were used to calculate cardiac intervals. The QRS interval is the time the segment of the ECG that corresponds to depolarization of the ventricles.
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan.
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan.
Change From Time Matched Baseline in Mean Individually-Corrected QT (QTcI) Values of Lasmiditan and Moxifloxacin Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose The corrected QT interval, individualized (QTcI) is a measurement of the electrical impulses through the largest part of the heart muscle individualized for participant pre-dose values. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.
Change From Baseline in Mean Cardiac Intervals: RR Interval of Lasmiditan and Moxifloxacin Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose ECGs were used to calculate cardiac intervals. The RR interval is the time between two R waves.
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
🇩🇪Berlin, Germany